NOTRELOAD AI
  • NOTRELOAD AI
  • Stocks BUZZ.
  • XYZ.
  • XY.
  • #TrumpTrade
  • Invest ↗
Sign in Subscribe

Morgan Stanley Maintains Bullish Stance on Elf Beauty Despite Rhode's Q2 Miss

Morgan Stanley analyst remains confident in Elf Beauty's growth despite Rhode brand's lower-than-expected June quarter revenue, citing strong September Sephora launch and maintaining $170 target.

Morgan Stanley Maintains Bullish Stance on Elf Beauty Despite Rhode's Q2 Miss
Credit: Rhode
Already have an account? Sign in.
10/20/2025 · 3:37 PM
ELF
/ Read more

Feed↓

Neuphoria Therapeutics pipeline
10/20/2025 · 5:15 PM

Neuphoria's Social Anxiety Treatment Fails Phase 3 Trial

Neuphoria's AFFIRM-1 Phase 3 trial for BNC210 social anxiety treatment misses all endpoints. Company halts SAD program, reviews options.

/ Subscriber only
AAV-mediated gene therapies for glaucoma and uveitis
10/20/2025 · 5:02 PM

Raymond James Launches MeiraGTx Coverage with Strong Buy Rating

Raymond James initiates MeiraGTx with Strong Buy rating and $29 price target, highlighting company's manufacturing platform and two major commercial opportunities in xerostomia and Parkinson's disease.

/ Subscriber only
Exelixis logo
10/20/2025 · 4:28 PM

William Blair Maintains Buy Rating on Exelixis Following Positive Cancer Trial Results, Despite Safety Concerns

William Blair analyst Andy Hsieh reaffirms Buy rating on EXEL stock after Phase III trial shows zanzalintinib combination therapy improves survival in metastatic colorectal cancer patients.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe